ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
3.080
-0.020 (-0.65%)
Oct 30, 2025, 4:00 PM EDT - Market closed
ProKidney Revenue
ProKidney had revenue of $221.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $527.00K. In the year 2024, ProKidney had annual revenue of $76.00K.
Revenue (ttm)
$527.00K
Revenue Growth
n/a
P/S Ratio
1,725.66
Revenue / Employee
$2,583
Employees
204
Market Cap
909.42M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 76.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
PROK News
- 1 day ago - ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference - GlobeNewsWire
- 10 days ago - ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2025 - GlobeNewsWire
- 5 weeks ago - ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy - Seeking Alpha
- 7 weeks ago - ProKidney Corp. (PROK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - ProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 2 months ago - ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference - GlobeNewsWire
- 2 months ago - ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates - GlobeNewsWire
- 3 months ago - ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel - GlobeNewsWire